Filling in for Ed Silverman, STAT provides uninterrupted pharma news this Friday before the Memorial Day weekend. Novo Nordisk’s Ozempic showed promising results in a trial for type 2 diabetes and chronic kidney disease, reducing cardiovascular and all-cause deaths. Eli Lilly is investing $5 billion to expand an Indiana facility for manufacturing obesity and diabetes medications, addressing nationwide supply shortages. This investment, totaling $9 billion, is the largest in U.S. drug manufacturing. Exclusive to STAT+ subscribers, this article highlights key developments in the pharmaceutical industry, showcasing advances in treatments and investments to meet growing demand.
Source link
We’re watching positive data for Ozempic, a Lilly factory expansion
